Phase III clinical trial - Sein métastatique RH+

EMERALD
Sein métastatique RH+
Ouvert depuis le: 07.09.2020
Site: Paris
Ouvert depuis le: 08.14.2019
Site: Saint-Cloud
Public cible
Adulte
ELACESTRANT MONOTHERAPY VS. STANDARD OF CARE FOR THE TREATMENT OF PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER FOLLOWING CDK4/6 INHIBITOR THERAPY: A PHASE 3 RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER TRIAL
Description de l'essai

While patients with ER breast cancer generally respond well to initial endocrine treatment, the resistance of the endocrine system (de novo and acquired) still represents a clinical challenge. The elacestrant is a new selective SERD with several characteristics that suggest its best efficacy in its category and an improvement over the fulvestrant and other treatments currently available in this population. In addition to an oral route of administration, non-clinical data have shown its efficacy in models of breast cancer IN the presence of the mutant and wild-type ESR1 gene (WT), and suggest that the elacestrant may have better activity anti-tumor in models with an ESR1 mutation compared to fulvestrant.